Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By



Executive Summary

Fueled by a spate of new product approvals and a constantly improving revenue picture, generic companies have caught and held the attention of investors in the first half of 1986. Generic issues were late joining the yearlong market rally, but they have shown a resilience of late in the market's recent downturn, with some moving toward historic highs as their brand name counterparts pulled back. Of the four exclusively generic companies on the "F-D-C" Weekly Index, three advanced during the week ended May 16, and one remained unchanged. Leading the gainers was Mylan (up 3-1/2 to 26-1/4), followed by Zenith (up 2-3/8 to 32-1/8) and Biocraft (up 1/8 to 10-3/4). Bolar was unchanged at 24-3/8. Mylan moved sharply on news of the companies recent ANDA approval for the antidepressant doxepin, which recently went off patient. Only two of the remaining companies on the Pharmaceutical Component -- Merck (up 2-1/4 to 182-1/8) and Marion (up 1/8 to 70-3/8) gained ground during the week. Merck, which traded as high as 187-1/2 on Wednesday, was a victim of profit taking the last two trading sessions. The runup on Merck stock may have been precipitated by a recent analyst report which valued the company in excess of $200 a share. Chart omitted.

You may also be interested in...

Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data

Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011

FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance

FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials

Shire Hopes To Sow Future Deals With $50M Venture Fund

Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth



Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts